Negative effects during multicomponent group-based treatment: A multisite study
Negative effects during multicomponent group-based treatment: A multisite study
复制标题
DOI：
10.1080/10503307.2022.2095237
复制
发表时间：
2022-07-01
影响因子：
3.9
通讯作者：
Boehnke，Jan R.
中科院分区：
文献类型：
--
作者：
Pourova，Martina;Rihacek，Tomas;Boehnke，Jan R.
团体治疗中的负面效应（内斯）仍然是一个研究不足的领域。本研究的目的是探讨各种类型的内斯在一个多组分组为基础的treatment.Method的患病率，并确定其predictors.A共330例患者参加了一个多组分组为基础的治疗招募在7个临床站点。在治疗结束时，使用负效应问卷（NEQ）测量内斯。项目水平的描述性分析进行了探索的各种类型的内斯的患病率，和结构方程模型被用来确定这些内斯.Results预测：内斯的最常见的类型是症状的恶化，和一个最常见的项目是不愉快的记忆的重现。内斯的预测因素包括整体的痛苦水平，述情障碍，附件回避，低工作联盟，问题驱动，和更糟糕的结果;心理的心态是一个保护因素。结论：患者谁经历了更高水平的痛苦，在治疗的开始，谁认为小组工作联盟的问题，谁经历了高的会话情绪唤起他们的问题似乎是特别容易报告内斯。此外，研究结果不支持内斯是治疗改变的先决条件的假设。ISRCTN.org
ObjectiveNegative effects (NEs) in group treatments remain an under-researched area. This study aimed to explore the prevalence of various types of NEs in a multicomponent group-based treatment and to determine their predictors.Method:A total of 330 patients participating in a multicomponent group-based treatment were recruited across seven clinical sites. At the end of treatment, the Negative Effects Questionnaire (NEQ) was used to measure NEs. Item-level descriptive analysis was conducted to explore the prevalence of various types of NEs, and structural equation modeling was used to determine predictors of these NEs.Results:The most frequently reported type of NEs was the worsening of symptoms, and the single most frequently reported item was the resurfacing of unpleasant memories. Predictors of NEs included the overall distress level, alexithymia, attachment avoidance, low working alliance, problem actuation, and worse outcomes; psychological mindedness was a protective factor.Conclusion:Patients who experience higher levels of distress at the beginning of treatment, who perceive the group working alliance as problematic, and who experience high in-session emotional arousal related to their problem seem to be especially prone to reporting NEs. Furthermore, the findings do not support the assumption that NEs are a prerequisite for therapeutic change.Trial registration:ISRCTN.org identifier: ISRCTN13532466.